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The WT1 protein was originally believed to func-tion as a tumor suppressor. Early studies showed that the protein repressed the transcription of sev-
eral oncogenic proteins, such as PDGF-A, transforming 
growth factor–b, EGF receptor, and insulin-like growth 
factor–I receptor, and increased the expression of genes 
that prevented malignant transformation, such as E-cad-
herin, and proapoptotic proteins (reviewed by Yang et 
al.46). However, subsequent studies showed that the abil-
ity of WT1 to transcriptionally activate or repress a puta-
tive target depended largely on which cell type was being 
used, the isoforms studied, the number of WT1 binding 
sites present on the target promoter, and other factors (re-
viewed by Yang et al.46). Moreover, the escalating inci-
dence of its discovery in malignant cells from several dif-
ferent tissue types (reviewed by Sugiyama37) implicated 
WT1 in oncogenesis. A key regulator of various devel-
opmental processes, WT1 expression was known to be 
switched off as tissues developed into the normal adult 
stage.15,16,19,35 However, wildtype WT1 was found to be 
expressed in leukemias and other hematopoietic malig-
nancies, lung and breast cancers, gastrointestinal cancers, 
sarcomas, tumors in the head and neck, reproductive or-
gan neoplasms, and gliomas (reviewed by Sugiyama37). 
In most or all of these tumors, WT1 expression appeared 
to play a decisive role in promoting proliferation, inva-
sion, and/or angiogenesis.3,6,7,10,11,18,22,24–31,34,36,38,39,42 
We have previously demonstrated WT1 expression in 
approximately 80% of glioma cell lines and tumor speci-
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mens.5 The predominant WT1 isoform expressed in these 
cells contained a 17–amino acid peptide coded for by 
exon 5 and the tripeptide KTS between zinc fingers 3 and 
4 (WT1 +/+). Our studies showed that glioma cells that 
had endogenous WT1 expression relied heavily on this 
protein for their growth and motility.3,6 WT1 also con-
ferred upon these cells resistance to radiation therapy and 
some chemotherapeutic agents.3,4
In the current study, we examined 2 additional GBM 
cell lines—U1242-MG and GBM-6—for the expression 
and function of WT1. Previous studies have shown that 
these 2 cell lines are highly invasive and mimic the pa-
thology of GBM when implanted orthotopically in athy-
mic mice.12,49 Endogenous expression of WT1 was not-
ed in both these cell lines. We also observed that WT1 
profoundly influenced cellular invasiveness in these cell 
lines.
The question that arose from these observations then 
was: how was WT1 mediating these effects in glial neo-
plasms?
Given its structural identity—a zinc finger transcrip-
tion factor—and its functional history, it seemed logical 
that WT1 might regulate the transcription (or posttran-
scriptional expression) of other genes that might then di-
rectly cause the above-mentioned effects. Therefore, to 
identify which genes might vary in glioma cells in their 
expression patterns as a result of WT1-mediated regula-
tion, we used gene microarray analysis to characterize 
differential gene expression. This method permits rapid 
screening of thousands of genes to find the possible can-
didate genes that are differentially expressed as a result 
of any manipulations. Our analyses revealed the identity 
of some such presumed or established oncogenes whose 
levels paralleled that of WT1 in glioma cells—PDGF-D, 
TYMS, INPP5A, CD97, and FAM57A. Genes whose ex-
pression levels were increased as a result of WT1 suppres-
sion, on the other hand, included putative tumor suppres-
sors, such as LZTS1, TIMP3, MAFF, and WIPI1. We then 
sought to ascertain if there was any correlation between 
the expression levels of WT1 and these candidate target 
genes in the U1242-MG and GBM-6 cells.
Our experiments showed that CD97 was significantly 
downregulated in all 3 cell lines investigated—U251-MG, 
U1242-MG, and GBM-6. We selected CD97 for further 
investigation, based on its consistent and direct correla-
tion with WT1 across the GBM cell lines examined and 
because of its putative roles in facilitating cell invasive-
ness and neoangiogenesis in gastrointestinal and thyroid 
tumors.1,14,21,41,43 This is the first time that expression of 
this oncogene has been reported in neoplastic glial cells.
CD97 is a cell surface receptor that belongs to the 
adhesion G-protein–coupled receptor (GPCR) family. It 
is therefore characterized by heptahelical hydrophobic 
segments that form the 7 transmembrane domains, an 
extracellular N terminus containing EGF-like structural 
domains (comprising the a-subunit), and an intracellular 
C terminus.47 Through alternative splicing of the mRNA 
transcript, 3 isoforms of the a-subunit of CD97 can be 
generated that differ in the number of EGF repeats they 
contain; these isoforms are hCD97 (EGF 1, 2, 5), hCD97 
(EGF 1, 2, 3, 5), and hCD97 (EGF 1, 2, 3, 4, 5).13 Also 
present in the amino-acid sequence of the extracellular 
segment, after the EGF-like repeats and before the first 
membrane-spanning sequence at position 318, is an RGD 
motif. This motif acts as a binding site for several classes 
of integrins, which are known to mediate attachment to 
the extracellular matrix and to other cells.13 The ligands 
that have been found to bind CD97 include CD55/decay 
accelerating factor (DAF) (involved in protection from 
complement-mediated attack and lysis), chondroitin sul-
fate (a glycosaminoglycan that affects cell attachment), 
and a5b1 integrin.41 Interestingly, the intracellular signal-
ing mechanism(s) by which CD97 and other adhesion-
GPCR family members might act is (are) yet unclear.20
Expression of CD97 has been reported mainly in 
leukocytes, and in this group, it has been found pre-
dominantly in myeloid cells. CD97 expression has also 
been reported in smooth muscle cells and in epithelial 
tumors.41 Its expression in thyroid carcinoma cells has 
been linked with promoting de-differentiation,1 while 
in colorectal and gastric carcinomas and fibrosarcomas, 
its expression has been associated with cellular invasive-
ness.20 Our results corroborated the findings from these 
earlier studies and we confirm that in glioma cells, also, 
CD97 appears to influence cellular invasiveness. Future 
studies will seek to confirm whether WT1 regulates ex-




Cells from the human glioma cell line U251-MG 
were obtained from ATCC; U1242-MG cells were a kind 
gift from Dr. James Van Brocklyn (Ohio State Universi-
ty), and GBM-6 cells were generously provided by Dr. C. 
David James (University of California, San Francisco) via 
Dr. Paul Dent (VCU). All cells were cultured in DMEM 
containing 10% fetal bovine serum, glutamine, nones-
sential amino acids, and 1% penicillin-streptomycin in a 
humidified atmosphere of 5% CO2. Normal human astro-
cyte RNA (catalog #1805) was procured from ScienCell 
Research Laboratories.
Short Interfering RNA Transfections
Cells were plated in 6-well plates at a density of 1.5–
2 × 105 cells per well. Twenty-four hours after plating, the 
cells were transfected as described previously.4 Cells were 
divided into the following groups: those that had only Oli-
gofectamine (Invitrogen) added to them (ctrl), those that 
were treated with nontargeting siRNA control (scr), and 
those that had been treated with siRNA targeting WT1 or 
CD97 (si). The final concentration of nontargeting siRNA 
control, anti-WT1 siRNA, and anti-CD97 siRNA was 100 
nM, a concentration that was determined by performing 
optimization experiments. Twenty-four hours after trans-
fection, 10% DMEM supplemented with 1% penicillin-
streptomycin was added. Forty-eight hours after transfec-
tion, the cells were harvested with trypsin, and following 
resuspension of the cell pellet in 10% DMEM, the cells 
were replated for RNA extraction for qRT-PCR and mi-
croarray analyses, protein extraction for Western blotting, 
and cell proliferation and/or invasion assays.
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RNA Extraction
RNA was extracted using Trizol (Invitrogen) accord-
ing to the manufacturer’s protocol. Following RNA ex-
traction, the RNA content was quantified using a spectro-
photometer, and approximately 12 mg of RNA per sample 
was subjected to DNase treatment using RQ1 DNase 
(Promega). Samples were then analyzed using qRT-PCR. 
Synthesis of probes and primers for anti-WT1 siRNA was 
carried out at the VCU Nucleic Acid Research Facilities. 
The Taqman primer mixes for the target genes were pur-
chased from Applied Biosystems. All qRT-PCR reactions 
were performed at the VCU Nucleic Acid Research Fa-
cilities.
Western Blotting
Protein was extracted from cell lines using SDS buf-
fer (50 mM Tris-C1, 1% SDS, 10% glycerol) supplemented 
with protease inhibitors. The concentration of protein was 
determined by DC protein assay (Bio-Rad). For protein 
analysis of cells transfected with anti-WT1 siRNA, 10 mg 
of total protein lysate was separated by SDS-polyacryl-
amide gel electrophoresis and transferred to nitrocellulose 
membrane according to the manufacturer’s protocol (Invi-
trogen). The membrane was then blocked with 5% nonfat 
milk solution for 1 hour at room temperature. Mouse anti-
WT1 monoclonal antibody (1:200 dilution, clone: 6F-H2, 
Dako) and rabbit anti-CD97 polyclonal antibody (1:200, 
Abcam) were diluted in blocking buffer, and the blots were 
incubated with the respective primary antibodies over-
night at 4°C. After this, the membranes were washed 6 
times in Tris-buffered saline containing 0.05% Tween-20 
before and after a 1-hour incubation at room tempera-
ture with horseradish peroxidase–conjugated anti–mouse 
(1:2000) and anti–rabbit (1:3000) secondary antibodies di-
rected against anti-WT1 and anti-CD97, respectively. An-
ticyclophilin A monoclonal antibody (1:30,000, Upstate 
Biotechnology) was used as a control for protein loading. 
Blots were developed using Pierce SuperSignal West Dura 
Substrate.
Cell Proliferation Assay
Cellular proliferation was measured at specified time 
points after transfection using the CellTiter-Glo lumines-
cent cell viability assay (Promega). The cells that were 
plated in opaque 96-well plates 48 hours after transfec-
tion were lysed for 15 minutes in CellTiter-Glo ATP vi-
ability assay reagents as per the protocol. Relative lumi-
nescence was then detected on a LUMIstar luminescence 
plate reader (BMG Labtech).
Invasion Assay
Matrigel (BD Biosciences), previously aliquoted, was 
thawed at 4°C on ice overnight before use. Forty-eight 
hours posttransfection, cells were plated on Matrigel-
coated 8.0-mm pore polycarbonate membrane inserts of 
6.5-mm Transwell plates (Corning) at a density of 5000 
cells/500 ml. Ninety-six hours following transfection, 
the medium was removed from the filters and the lower 
chambers, the upper part of each filter was scraped with 
cotton-tipped applicators to remove the cells that had not 
invaded, and each lower chamber was rinsed with phos-
phate-buffered saline. Then 200 ml of 1× trypsin-EDTA 
(prepared by diluting in phosphate-buffered saline a 10× 
solution of 0.5% trypsin-EDTA containing 5 mg/ml of 
trypsin with 4.81 mM Na-EDTA in 146.55 mM sodium 
chloride) was added to each chamber to harvest the cells, 
and after a 5-minute incubation at 37°C, 800 ml of 10% 
DMEM was used to neutralize the enzyme. The lower 
part of each filter was rinsed with medium to collect cells 
that had invaded through the Matrigel-coated insert but 
had not adhered to the base of the lower chamber. After 
centrifugation at 1000 rpm for 5 minutes to collect the 
cells, the supernatant was removed from each tube, and 
fresh medium was added to a volume of 500 ml. The en-
tire volume was then plated (100 ml/well) into an opaque 
96-well plate for assaying the ATP content as described 
above.
Gene Expression Profiling
The microarray reactions were performed using the 
Affymetrix GeneChip standard protocol as previously 
described.9 Quality analyses of all RNA samples, as well 
as cDNA and cRNA synthesis products, were carried out 
before proceeding further by running 1 ml of every sam-
ple in RNA 6000 Nano or DNA 7500 LabChips on the 
2100 Bioanalyzer (Agilent), following the manufacturer’s 
protocol. Quality control criteria included cDNA and 
cRNA synthesis products within median lengths of 2.0 
and 3.0 kb, respectively, and 3 /́5ʹ ratios close to 1.00 for 
the housekeeping genes, GAPDH and β-actin.8 The “sig-
nificance-score” algorithm (S-score) developed by Dr. Li 
Zhang was used to produce a score for the comparisons 
of the expression summaries between cell groups.48 The 
Minimum Information About a Microarray Experiment 
guidelines have been met, and the microarray raw data 
have been deposited with the National Center for Bio-
technology Institute Gene Expression Omnibus—acces-
sion number GSE22578.
Statistical Analysis
All comparisons were between 2 cell groups: 1) cells 
treated with nontargeting siRNA or untreated cells; and 
2) cells treated with siRNA directed against WT1 or 
CD97. Each experiment was replicated at least 3 times, 
and results are presented as mean values with SDs. The 
Student t-test (2-tailed, paired) was used, and a calculated 
p value of ≤ 0.05 was considered statistically significant. 
Results
Expression and Function of WT1 in U1242-MG and 
GBM-6 Cells
Using Western blotting, we detected WT1 expression 
in U1242-MG and GBM-6 cell lines (Fig. 1A). Cell ex-
tracts from the prostatic carcinoma cell line (PC3) were 
used as a positive control for WT1. Both GBM-6 and 
U1242-MG show the characteristic WT1 double band, 
suggesting the possibility of the + and - exon 5 variants 
that differ by 17 amino acids, at the predicted molecular 
weight level (52–54 kDa).
After using siRNA directed against WT1, we con-
firmed efficient silencing of this transcription factor by 
A. Chidambaram et al.
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qRT-PCR (Fig. 1B). On the 3rd day after transfection, we 
found that the level of WT1 mRNA in GBM-6 cells treat-
ed with anti-WT1 siRNA was 14.44% (± 2.89%) of that 
seen in their control counterparts that had been treated 
with nontargeting siRNA (p ≤ 0.001). In U1242-MG cells, 
there was less knockdown (50.47% [± 3.49%] of control 
levels), which was nevertheless highly significant (p ≤ 
0.001). 
We observed that these decreases in cellular content 
of WT1 remarkably depressed the invasive capacity of 
these cells (Fig. 1C). In GBM-6 cells, there was nearly 
a 95% decrease (± 22.65%) in the ability of the anti-WT1 
siRNA–treated cells to invade through the Matrigel-coat-
ed filter (p ≤ 0.05) compared with the control cells, while 
in U1242-MG cells, silencing of WT1 caused a decrease 
in cellular invasiveness to 20.62% (± 1.12%) of the control 
cells (p ≤ 0.001). These differences in the ability to invade 
could potentially be accounted for by decreased prolifera-
tive rates in the siRNA-transfected cells versus control 
cells. Hence, we performed cell viability assays on these 
same groups of cells. Our results showed that the growth 
rates of control and siRNA-treated cells were not signifi-
cantly different across 3 independent experiments (data 
not shown). Also, based on our previous experiments we 
found no statistically significant differences between un-
treated cells and cells treated with nontargeting siRNA 
(scr). Hence, we show only comparisons between groups 
treated with nontargeting and targeting siRNA. 
Gene Expression Profiling: Putative Target Genes for WT1 
in U251-MG Glioma Cells
To ascertain the identity of the potential target genes 
for WT1 in the particular context of glioma cells, we 
chose to perform gene expression profiling experiments. 
On 3 separate occasions, U251-MG cells were treated 
with Oligofectamine alone (ctrl), nontargeting RNA (scr), 
or siRNA against WT1. After confirming WT1 knock-
down with qRT-PCR in the siRNA-treated samples each 
time, microarray analyses were carried out using the Af-
fymetrix GeneChip Standard protocol. Quality control 
checks were performed, and RNA samples that met the 
criteria described in detail in our previous studies40 were 
used for microarray analyses. The S-score analyses of the 
data obtained in the 3 sets of experiments are summa-
rized in Tables 1 and 2, revealing a total of 27 genes that 
were downregulated and 11 genes that were upregulated, 
respectively, in response to WT1 silencing. These genes 
passed 2 separate levels of stringency for being declared 
significantly altered—the S-score, which establishes 
sig nificance at the univariate level, and the Benjamini-
Hoch berg correction, which corrects for multiple com-
parisons.38 The fold change of each gene in these tables 
is expressed as the mean value of the results for that gene 
from the 3 different microarray experiments. For clarity, 
standard deviations for these values are not shown, but 
they represented up to 30% of the mean values. Super-
Fig. 1. Expression and function of WT1 in U1242-MG and GBM-6 cells. A: WT1 expression in GBM-6 and U1242-MG cells 
was detected using Western blotting. Twenty micrograms of protein was loaded in each lane. Cell lysates in Lanes A, B, and C 
are from PC3 (control), GBM-6, U1242-MG cells, respectively. B: WT1 silencing was confirmed using qRT-PCR (p ≤ 0.001). 
WT1 mRNA levels in anti-WT1 siRNA–treated cells are first normalized to the level of the loading control and expressed as a 
percentage of the control cells. **p ≤ 0.001. C: WT1 downregulation was associated with a decrease in GBM-6 and U1242-MG 
cellular invasiveness at Day 4 posttransfection (*p < 0.05, ***p < 0.001). Cell invasiveness in WT1-silenced cells was assessed 
by using the CellTiter-Glo assay (RLU is a surrogate for cell number) to first quantify the number of cells that had invaded through 
the Matrigel in the si groups versus the scr groups and then expressing this value as a percentage of that seen in control (scr) 
cells. All experiments were performed in triplicate with separate cultured samples of tumor cells treated in parallel with siRNA 
against WT1 and corresponding controls.
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vised cluster analyses from 3 independent experiments 
based on these 38 genes showed that the “ctrl” and “scr” 
cell groups cluster together and separately from the “si” 
group of cells that were treated with siRNA (Fig. 2). Thus, 
Fig. 2 represents an experiment performed in triplicate 
over the course of multiple weeks, with separate cultured 
samples of U251-MG cells treated in parallel for knock-
down of WT1 expression with corresponding controls. 
To the left side of the heat map is a list of all the genes 
whose levels were found to be altered with this manipu-
lation. WT1 (highlighted in yellow) appears prominently 
downregulated as a result of our experimental treatment, 
confirming the successful downregulation using siRNA 
knockdown. Also, there is a high level of consistency 
in the patterns of up- or downregulation of the selected 
genes, among the corresponding replicates (ctrl, scr-, or 
si-treated) from the 3 experiments performed.
Among the genes that were downregulated with WT1 
silencing, implying a direct correlation, several (identi-
fied by searching the available literature) had either pu-
tative or established oncogenic roles in gliomas and/or 
other malignancies. These genes included ICK, INPP5A, 
TYMS, PDGF-D, CD97, EPAS1, FAM57A, KRT18, and 
HSPC111 (Table 1). Conversely, the genes that inversely 
correlated with WT1 levels included some prominent tu-
mor suppressors such as SSAT1, LZTS1, WIPI1, TIMP3, 
SOX11, MAFF, and DPYSL3.
Validation of Microarray Findings Using qRT-PCR
We used qRT-PCR to validate our microarray find-
ings, because it was quicker and more sensitive and would 
provide information pertaining to the gene expression lev-
TABLE 1: Gene expression profiling demonstrating the fold 





Gene Title si vs ctrl si vs scr
intestinal cell (MAK-like) kinase ICK 0.189 0.287
inositol polyphosphate-5-phos- 
 phatase, 40 kDa
INPP5A 0.25 0.1649
chromosome 11 open reading frame 
 57
C11orf57 0.25 0.25
thymidylate synthetase TYMS 0.26 0.287
platelet-derived growth factor-D PDGF-D 0.26 0.176
LSM14A, SCD6 homolog A (S. cere- 
 visiae)
LSM14A 0.287 0.26
NADH dehydrogenase (ubiquinone) 
 1 alpha subcomplex, 1, 7.5 kDa
NDUFA1 0.287 0.287
dihydrolipoamide branched chain 
 transacylase E2
DBT 0.33 0.307
potassium channel tetramerisation 
 domain containing 12
KCTD12 0.33 0.33
CD97 molecule CD97 0.33 0.307
NECAP endocytosis associated 1 NECAP1 0.33 0.307
BTB (POZ) domain containing 1 BTBD1 0.33 0.307
endothelial PAS domain protein 1 EPAS1 0.353 0.287
hypothetical protein FLJ10357 FLJ10357 0.353 0.353
secretogranin II (chromogranin C) SCG2 0.353 0.233
mitofusin 1 MFN2 0.353 0.33
carboxypeptidase, vitellogenic-like CPVL 0.353 0.3789
LSM14A, SCD6 homolog A (S. cere- 
 visiae)
LSM14A 0.353 0.33
chromosome 14 open reading frame 
 13
C14orf135 0.3789 0.3789
uroporphyrinogen III synthase (con- 
 genital erythropoietic porphyria)
UROS 0.3789 0.33
family with sequence similarity 
 57, member A
FAM57A 0.3789 0.353
serine carboxypeptidase 1 SCPEP1 0.3789 0.33
NSFL1 (p97) cofactor (p47) NSFL1C 0.406 0.3789
hypothetical protein HSPC111 HSPC111 0.406 0.353
iron-sulfur cluster assembly 1 homo- 
 log (S. cerevisiae)
ISCA1 0.406 0.435
keratin 18 KRT18 0.406 0.3789
RNA binding motif, single stranded 
 interacting protein 1
RBMS1 0.406 0.353
* A total of 28 genes were downregulated (including WT1, not shown 
in table). Bold type indicates genes that have putative or established 
roles in oncogenesis. A total of 3 independent microarray experiments 
were conducted.
TABLE 2: Gene expression profiling demonstrating the fold 
change of genes that are significantly upregulated in 
WT1-silenced U251-MG cells*
Fold Change
Gene Title Gene Symbol si vs ctrl si vs scr
CD55 molecule, decay accelerat- 
 ing factor for complement (Cro- 





WD repeat domain, phospho- 
 inositide interacting 1
WIPI1 2.639 2.828
calcitonin receptor–like CALCRL 2.639 3.03
leucine zipper, putative tumor 
 suppressor 1
LZTS1 2.828 3.73
TIMP metallopeptidase inhibi- 
 tor 3 (Sorsby fundus dystro- 
 phy, pseudoinflammatory)
TIMP3 2.828 3.03
heme oxygenase (decycling) 1 HMOX1 2.828 2.828
SRY (sex determining region 
 Y)-box 11
SOX11 2.828 2.46
v-maf musculoaponeurotic fi- 
 brosarcoma oncogene ho- 
 molog F (avian)
MAFF 3.03 2.828
RAR-related orphan receptor B RORB 3.24 2.828
dihydropyrimidinase-like 3 DPYSL3 3.48 3.73
* A total of 11 genes were upregulated. Bold type indicates genes that 
have putative or established roles in suppressing cancers. A total of 3 
independent microarray experiments were conducted.
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els, which was of particular interest to us since we were 
assessing the potential transcriptional targets of WT1. For 
our validation experiments, we selected from among all 
the targets identified by microarray only those that had 
been implicated as having a relevant role in oncogenesis 
or tumor suppression based on literature search. As with 
the microarray studies, siRNA-transfection, scr-trans-
fection, and control (Oligofectamine alone) treated cells 
were prepared on 3 separate occasions, and RNA extracts 
were then subjected to qRT-PCR as described in Methods 
for the putative target genes. Furthermore, certain genes 
such as ICK, KRT18, and TIMP3 are not represented in 
the graph owing to lack of reproducible results. The 2-DDCT 
method was used to calculate fold changes in the mRNA 
expression levels of the candidate genes against b-actin 
mRNA. The values thus obtained for the si groups of cells 
were then compared with the corresponding values in the 
scr groups of cells. Figure 3 represents a comparison of 
the fold change of each candidate gene obtained from the 
qRT-PCR analyses (bar graph) against the corresponding 
value derived from the microarray analyses (line graph). 
We successfully substantiated the microarray results with 
qRT-PCR by showing that, with both sets of genes, there 
is a consistent trend toward down- or upregulation of their 
expression levels. In the case of the genes that were down-
regulated with WT1 silencing, the magnitude of the fold-
change values identified by means of qRT-PCR (range 
0.25 ± 0.04 to 0.53 ± 0.22) was seen to be close to or only 
slightly different from that of the fold-change values ob-
tained through the microarray experiments (0.16–0.35). 
With the inversely correlated genes, the fold-change val-
ues were much higher in the microarray results (2.6- to 
3.7-fold differences) than in the qRT-PCR results (range 
0.9 ± 0.21 to 1.9 ± 1.07). 
Confirmation of Putative Target Genes in U1242-MG and 
GBM-6 Cell Lines
We subsequently investigated whether these genes 
that were dysregulated in U251-MG cells were similar-
ly altered by WT1 silencing in U1242-MG and GBM-6 
Fig. 2. Supervised cluster analysis. Two-dimensional hierarchical clustering of samples and genes using Pearson (centered) 
correlation and average linkage. Three independent transfection experiments were performed for each microarray analysis.
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cells. Both of these cell lines were subjected to siRNA 
transfections targeting WT1, and nontargeting siRNA 
(scr) was used to generate appropriate controls. Again, 
for each cell line, results were generated from 3 indepen-
dent experiments. Using qRT-PCR, we found that from 
among the genes whose expression levels paralleled those 
of WT1, INPP5A, CD97, and TYMS were downregu-
lated in the si groups in both U1242-MG and GBM-6 
cells compared with scr groups (Fig. 4). In GBM-6 cells, 
the extent of knockdown of these genes was as follows: 
INPP5A—51.77% ± 0.26% (p ≤ 0.05); CD97—49.6% ± 
0.14% (p ≤ 0.01); and TYMS—52.4% ± 0.16%, (p ≤ 0.01). 
Additionally, in GBM-6 cells, the expression levels of 
PDGF-D and FAM57A in the siRNA-treated groups of 
cells were significantly decreased to 16.2% (± 0.06%; p 
≤ 0.01) and 44.1% (± 0.23%; p ≤ 0.05) of their scr coun-
terparts, respectively. In U1242-MG cells, the extent of 
knockdown of these candidate target genes (as a per-
centage of scr control) was as follows: INPP5A—65.5% 
± 0.11% (p ≤ 0.01); CD97—30.6% ± 0.09% (p ≤ 0.05); 
and TYMS—47.7% ± 0.04% (p ≤ 0.01). Additionally, in 
U1242-MG cells the expression of EPAS1, a potent an-
giogenesis facilitator, was also decreased with WT1 si-
lencing. The siRNA-treated U1242-MG cells had 77.5% 
of EPAS1 expression compared with their corresponding 
control values, although statistical significance could not 
be established. For the genes that microarray analyses 
demonstrated to be upregulated with WT1 silencing (that 
is, inversely correlated with WT1 expression), we found a 
trend toward an increase in DPYSL and MAFF (GBM-6) 
and WIPI1 (U1242-MG), but the high variability across 
the 3 independent experiments precluded the establish-
ment of statistical significance.
Analysis of Expression and Function of CD97 in GBM 
Cells
Based on our microarray findings and our confirma-
tory findings using qRT-PCR, we conducted promoter 
analyses to look for potential binding sites in the promot-
er regions of the genes that appeared to be differentially 
regulated by WT1 (data not shown). With the exception of 
PDGF-D (which had binding sites for Egr-1, but not spe-
cifically WT1), all the remaining candidate target genes 
were found to have at least 1 potential WT1 binding site 
in their promoter regions. This information, coupled with 
the consistent CD97 downregulation in all 3 GBM cell 
lines that had been treated with anti-WT1 siRNA, led us 
to further examine the role of CD97 in these cells with 
respect to its expression levels and consequent effects on 
cellular invasiveness.
We first determined the expression of CD97 at the 
protein level using Western blot analysis, which revealed 
that it was expressed in all 3 cell lines examined (Fig. 
5A). We then compared the mRNA expression levels of 
Fig. 3. Validation of microarray results. U251-MG cells were transfected with nontargeting siRNA (scr) or WT1-targeting 
siRNA (si). RNA samples extracted 48 hours following transfection were analyzed by qRT-PCR. Bar Graph: Fold-change 
values of siRNA-treated cells compared with scr controls (depicted by the dashed line at 1) calculated from qRT-PCR experi-
ments. Line Graph: Fold-change values calculated using microarray analyses. Value of scr is set at 1 (depicted by the dashed 
line). Transfection was performed on 3 parallel sets of cell cultures to generate these results. *p ≤ 0.05; **p ≤ 0.01.
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CD97 in normal human astrocytes to those in the GBM 
cell lines—U251-MG, U1242-MG, and GBM-6—and 
found 6- to 21-fold greater CD97 mRNA levels in the 3 
cell lines than in normal human astrocytes (Fig. 5B).
Subsequently, CD97 expression in all 3 glioma cell 
lines was downregulated by siRNA transfection methods, 
and the biological effects of this manipulation were ex-
amined. As shown in Fig. 5C, qRT-PCR analyses dem-
onstrated a significant knockdown in all 3 cell lines even 
at Day 4 posttransfection (p < 0.05). In U251-MG cells, 
there was a nearly 50% decrease in CD97 mRNA levels 
at this time point, whereas in GBM-6, there was a nearly 
80% decrease. In U1242-MG cells, there was a less re-
markable knockdown (20% decrease compared with the 
control cells), which was nevertheless statistically signifi-
cant. When plated on Matrigel-coated filters of Transwell 
plates, we found that these decreases in CD97 mRNA 
levels were associated with significantly lower cellular in-
vasiveness capacities (Fig. 5D). In U251-MG cells treated 
with siRNA against CD97, the cellular invasiveness po-
tential was decreased to roughly 53.85% of that of the 
control counterparts. In U1242-MG cells, even a modest 
decrease in CD97 RNA levels was associated with a strik-
ing decrease in invasiveness (25.5% of control), whereas 
in GBM-6 cells, the 80% decrease in CD97 mRNA levels 
caused a nearly 50% decrease in invasive capacity. Thus, 
it is clear that the expression of CD97 is functionally sig-
nificant in glioma cells. We also examined the effects on 
cellular proliferation (if any) of knocking down CD97, 
even though such a role has not frequently been attributed 
to this molecule. Our findings showed that there were no 
significant differences between the proliferative rates of 
the control versus experimental groups across all the 3 
cell lines (data not shown).
Discussion
We have identified, using gene expression profiling, 
genes whose expression levels correlate directly or in-
versely with WT1 levels in the specific context of ma-
lignant gliomas. Of the 27 genes whose expression pat-
terns were positively correlated with that of WT1 (that is, 
downregulated with suppression of WT1 expression), 9 
candidates were selected for having established or puta-
tive oncogenic functions, based on published literature. 
Conversely, of the 11 genes whose levels were inverse-
ly correlated (upregulated with WT1 silencing), 7 have 
been implicated in the suppression of tumorigenesis. We 
have validated the microarray findings for these genes in 
U251-MG cells with qRT-PCR and have also confirmed 
these expression patterns in 2 other GBM cell lines. Our 
promoter studies revealed potential binding sites for WT1 
in the promoter regions of all but one of the putative tar-
get genes. In the lone exception—PDGF-D—the pro-
moter region did, however, show potential binding sites 
for the Egr-1 family of transcription factors. It has been 
established in previous studies23,35,45 that WT1 shares the 
consensus binding sequences recognized and bound by 
the Egr-1 family of proteins.
CD97 was uniformly downregulated in all 3 cell 
lines with WT1 silencing and displayed sites on its pro-
moter that could be theoretically bound by WT1. More-
over, CD97 is well established as a facilitator of tumor 
cell invasiveness in other malignancies. Given these 
considerations, we further examined the role of this pro-
tein in gliomas. This novel undertaking revealed that in 
glioma cells, as in gastrointestinal malignancies and the 
fibrosarcoma cell line HT-1080,20 the CD97 receptor fos-
ters cellular invasiveness, and decreasing its endogenous 
expression caused a significant and striking decrease in 
the ability of the cells to invade through Matrigel.
The complexity of the WT1 protein has long posed a 
formidable challenge to those who have ventured to study 
its varied functions. Because of its vastly differing roles 
in different cell types, categorizing this protein as a tu-
mor suppressor or an oncoprotein is difficult. In certain 
cells like the progenitor cells of the kidney, WT1 facili-
tates their exit from the cell cycle with subsequent dif-
ferentiation.15 In the neural and vascular progenitor cells, 
however, it has the exact opposite effect—facilitating 
proliferation and preventing differentiation.15 Hence, any 
conclusions about its role(s) must be made strictly in the 
context of the cell type examined. We selected the micro-
array technique to study differences in gene expression 
arising out of manipulating the levels of WT1 in glioma 
cells that expressed it endogenously. Moreover, silencing 
the endogenous expression of the protein to look for the 
resultant differences was a more appropriate model to ac-
Fig. 4.  Confirmation of altered regulation of target genes across dif-
ferent glioma cell lines transfected with anti-WT1 siRNA. Experiments 
were performed in triplicate for both GBM-6 and U1242-MG cells. The 
x-axes represent the target genes and the y-axes the fold change in si 
cells (value of scr set at 1, dashed line). *p ≤ 0.05; **p < 0.01. §§Genes 
that were not found to correlate/be expressed. 
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curately assess the possible functions of WT1 rather than 
overexpressing WT1 in a WT1 null cell line, due to the 
myriad variables (WT1 isoforms and concentration) as-
sociated with the latter technique.
Identifying the target genes via which WT1 might 
influence its role in the neoplastic transformation of glial 
cells was important for many reasons. First, as a regulator 
of transcriptional and posttranscriptional processes, WT1 
has the ability to coordinate many of the key aspects of 
glioma biology—proliferation, invasiveness, and angio-
genesis—by regulating the expression of the molecules 
that mediate these processes. Moreover, given the rapid 
progress that is being made in the field of immunologi-
cally targeting WT1,2,17,32,33 our findings help to fill in the 
missing links in understanding how it functions. Finally, 
knowing the identity of its molecular associates can help 
in devising therapeutic strategies that target one or more 
of these components. Since these components may belong 
to different intracellular signaling pathways, targeting 
them simultaneously could work synergistically to have 
even greater effects against malignant gliomas.
The identification of at least 9 candidate oncogenes 
that were suppressed and 7 putative tumor suppressors 
that were upregulated by WT1 silencing confirmed our 
hypothesis that in gliomas, WT1 has more of an onco-
genic function. Our study has also revealed for the first 
time that CD97 is aberrantly overexpressed in GBM 
cells. This protein has well-documented roles in mediat-
ing tumor cell invasion and even angiogenesis1,43 in other 
malignant cell types. In various gastrointestinal malig-
nancies, an increased expression of CD97 has been dem-
onstrated at the invading front of the tumor.14,21 Likewise, 
we have shown here that in glial neoplastic cells, also, 
it has a significant role in conferring invasiveness upon 
the cells. From our findings, it appears that in U1242-MG 
cells, the extent to which WT1 decreases cellular inva-
siveness roughly equals that seen with silencing of CD97 
expression. In U251-MG and GBM-6 cells, on the other 
hand, WT1 silencing causes a much more pronounced de-
crease in cellular invasiveness than that seen with CD97 
silencing alone. In both of these cell lines, expression of 
PDGF-D was also seen to be significantly decreased with 
lowered expression of WT1. It is well established that 
PDGF-D is a strong mitogenic and chemoattractant mol-
ecule that can initiate several malignant features, such as 
proliferation, invasion, and angiogenesis in brain tumors 
(reviewed by Wang et al.44). A more detailed examination 
of the relationship of this growth factor to WT1 undoubt-
edly merits further attention.
We restricted the scope of this study to examining 
the expression and function of CD97 in glioma cell lines 
to establish well-characterized in vitro model systems 
that will allow continuing investigation of the molecular 
mechanisms involved with WT1 overexpression and the 
Fig. 5. Expression and function of CD97 in GBM cells. A: Western blot showing CD97 protein expression (≈ 92 kDa) in 
U251-MG, U1242-MG, and GBM-6 glioma cells. Ten micrograms of protein was loaded in each lane. Rabbit polyclonal Ab (Ab-
cam) was used to detect CD97 (1:200). B: Quantitative RT-PCR demonstrated minimal expression of CD97 in normal human 
astrocytes (NHA) and a 6- to 21-fold increase in expression in the GBM cell lines investigated. C: Using siRNA directed against 
CD97, we confirmed a significant knockdown in CD97 RNA in the tumor cells on Day 4 posttransfection by qRT-PCR in U251-MG, 
U1242-MG, and GBM-6 cells. D: Treatment of U251-MG, U1242-MG, and GBM-6 cells with siRNA against CD97 resulted in a 
significant decrease in their ability to invade through the Matrigel-coated filters of transwell plates compared with cells that were 
treated with nontargeting siRNA. Cell invasiveness in CD97-silenced cells was expressed by using the CellTiter-Glo assay to first 
quantify the number of cells that had invaded through the Matrigel in the si groups versus scr groups and then expressing this 
value as a percentage of that seen in control (scr) cells. Three independent cultures of U251-MG, GBM-6, and U1242-MG cells 
were transfected with corresponding controls. *p < 0.05.
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correlated CD97 expression. Further, we chose to com-
pare CD97 expression in these cells to that in normal hu-
man astrocytes as there was very little data describing 
expression of this proinvasive receptor molecule in the 
normal brain tissue components. Clearly, evaluation of 
CD97 expression in vivo, both in animal models and in 
human tumor samples, will also be needed. Along these 
lines, we can confirm that preliminary data from studies 
conducted by our laboratory have revealed CD97 mRNA 
expression by a high proportion of individual human 
glioma samples (data not shown). The detection of sig-
nificantly higher levels of CD97 in the GBM cell lines 
and tumor specimens than is found in normal brain glia 
argues for a pathogenic role for this protein. Our results 
lay the groundwork for further analyses of the functional 
significance of CD97 using more sophisticated experi-
mental techniques, such as brain slice invasion assays or 
in vivo studies.
We chose to downregulate CD97 expression as a 
more appropriate method in the initial evaluation of its 
inherent functional role. Future studies will seek to first 
identify the exact isoform(s) of CD97 (containing 3, 4, 
or 5 EGF repeats) that is (are) expressed in glioma cells. 
Upregulation of the identified isoform(s) in these cells can 
then be performed to confirm an increase in cellular inva-
siveness. Finally, although our promoter studies suggest 
putative binding sites for WT1 on the CD97 promoter, 
definitive evidence is still required to demonstrate WT1-
mediated transactivation of CD97 expression.
The ability to localize and therapeutically target the 
invading neoplastic cells in situ has for a long time been 
a challenge in the treatment of brain tumors. With the 
identification of CD97 expression and function in glioma 
cells, determining its ability to serve as a reliable marker 
of invasiveness using immunohistochemical staining of 
glioma tumor specimens opens up a potentially interest-
ing line of investigation. Another option may be to devise 
a therapeutic strategy aimed at targeting the CD97 re-
ceptor, which could be relatively safe, since it is virtually 
absent in normal human astrocytes and the glia of normal 
brain (data not shown). Further investigations are also 
necessary to determine the effect of targeting the CD97 
receptor on angiogenesis, as it is also known to affect this 
process.
Conclusions
Our studies emphasize the importance of WT1 in 
promoting GBM cellular invasiveness and reveal the 
identities of its putative target genes in glioma cells. We 
also show, for the first time in glioma cells, the expression 
and proinvasive function of CD97. Our study thus opens 
important new avenues in the field of glioma biology. 
More in-depth analyses of these molecules should carry 
us further in our attempts to find novel and more effective 
therapeutic targets for the treatment of GBM.
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